IMWG consensus on risk stratification in multiple myeloma (Q38131380)

29 August 2017

IMWG consensus on risk stratification in multiple myeloma (English)

1 reference

29 August 2017

R Fonseca

4

0 references

Angela Dispenzieri

A Dispenzieri

International Myeloma Working Group

2

0 references

15

International Myeloma Working Group

1 reference

29 August 2017

H Avet-Loiseau

14

0 references

Saad Z Usmani

S Usmani

12

0 references

Brian Durie

13

B G M Durie

1 reference

29 August 2017

W J Chng

1

1 reference

29 August 2017

C-S Chim

3

1 reference

29 August 2017

H Goldschmidt

5

1 reference

29 August 2017

S Lentzsch

6

1 reference

29 August 2017

N Munshi

7

1 reference

29 August 2017

A Palumbo

8

1 reference

29 August 2017

J S Miguel

9

1 reference

29 August 2017

P Sonneveld

10

1 reference

29 August 2017

M Cavo

11

1 reference

29 August 2017

26 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

28

1 reference

29 August 2017

2

1 reference

29 August 2017

269-277

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.247

29 August 2017

0 references

cites work

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

How I treat multiple myeloma in younger patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Survival and years of life lost in different age cohorts of patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Role of genetics in prognostication in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Impact of early relapse after auto-SCT for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Approach to the treatment of multiple myeloma: a clash of philosophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Clonal competition with alternating dominance in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

A gene expression signature for high-risk multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

A novel measure of chromosome instability can account for prognostic difference in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.247

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

21 January 2018

1 reference

12 December 2020

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

1 reference

12 December 2020

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma

1 reference

12 December 2020

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

12 December 2020

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

1 reference

12 December 2020

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

12 December 2020

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

1 reference

12 December 2020

Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group

1 reference

12 December 2020

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

1 reference

12 December 2020

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

1 reference

12 December 2020

Treatment of multiple myeloma

1 reference

12 December 2020

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.247

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference